Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

venous thromboembolism

Marketing strategy in complex environments

Age-old treatment protocols are being replaced with new and innovative treatment paradigms that will revolutionise the healthcare industry for years to come. Kulveer Singh and Mark Assenti talk through what...

Blue Latitude Health

- PMLiVE

Bayer: Post-truth politics severely handicaps innovation

And firm also voices its concerns over Brexit

- PMLiVE

Xarelto and Eylea continue to dominate Bayer’s pharma sales

And firm looks for turnaround in 2017 from Stivarga

- PMLiVE

NICE U-turn on Imbruvica sees the leukaemia therapy backed for NHS use

Institute reverses its initial verdict on Janssen's oncology treatment

- PMLiVE

Bayer appoints president of Americas pharma business

Dr Carsten Brunn to lead operations across the US, Canada, Central and Latin America

- PMLiVE

J&J pondering future of diabetes device assets

Three diabetes care subsidiaries under review as firm forecasts measured 2017 sales

- PMLiVE

Bayer appoints head of EU liaison office

Volker Koch-Achelpöhler succeeds Bernd Halling

Bayer promotes Robert LaCaze

He becomes EVP of new oncology strategic business unit

Bayer symbol

Bayer nets speedy US review for regorafenib in liver cancer

Priority review in HCC boosts hopes for rejuvenation of Stivarga to combat declining sales

Bayer symbol

Bayer helps bankroll new stem cell company BlueRock

Start-up receives $225m to develop cardiovascular and neurodegenerative disease therapies

- PMLiVE

Novartis’ AMD drug pegpleranib fails phase III programme

Plans for Lucentis-boosting duel-therapy stumble as trial data show no additional benefit

- PMLiVE

Janssen files Stelara follow-up guselkumab in Europe

Trial data shows J&J’s drug is more effective in treating psoriasis than AbbVie’s Humira

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links